🧬Computational analysis for diagnosis and prognosis in MDS by Elsa Bernard at #CETLAM2024. Diving in a paradise of mutations (MDS).

Abrimos la reunión anual #CETLAM2024 con Elsa Bernard hablándonos de “Computational oncology for prediction of MDS evolution and prognosis” en Recinte Modernista de Sant Pau

El Dr George Vassiliou Vassiliou Lab toma el relevo en la sesión educacional #CETLAM2024 para hablarnos de los últimos avances en hematopoyesis clonal.

🔮nice talk by George Vassilious about clonal hematopoiesis. Few mutant genes with different fitness related to age. TP53 is frequent but had slowly growing. TET2 seems more frequent in older patients…so, what else?#CETLAM2024 Grupo CETLAM

Alex Bataller, desde Houston, nos explica la dinámica genética de la LAM en la 1a recaída 📈 Grupo CETLAM #aml #genetics #houston

En la última ponencia de hoy, Alex Bataller analiza las características clinico-biológicas de la LMA en recaída. #CETLAM2024

💊 Alex Bataller from MDAnderson to his home at #cetlam!!

Comienza la reunión de trabajo de #CETLAM2024 con una actualización de los proyectos en curso y de los que están por venir 🧬🔬

Reunión de Grupo CETLAM día 2!

European LeukemiaNet 2022 risk classification in patients undergoing alloHSCT for AML: Identification of a very poor prognosis genetic group Really happy to share it with you! Thanks to all authors, especially to Maria Queralt Salas for the teamwork! onlinelibrary.wiley.com/doi/10.1111/bj… British Journal of Haematology

Check our poster at #EHA2024 presenting the preliminary results of the CETLAM project for NGS MRD assesment in AML! Hematología SantPau Grupo CETLAM

Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML ashpublications.org/blood/article-… Key takeaways Adverse risk CG, WT1, DNMT3A, FLT3ITD were associated with high rate of MRD+ by PCR & ⬆️ relapses In spite of high risk molecular features, MRD- overcome bad

ELN-risk classification for #AMLsm patients receiving less-intensive therapies (ELN 2024 Less-Intensive) ashpublications.org/blood/article/…

📍ELN 2017/2022 prognostic classifiers did not adequately stratify OS outcomes for #AMLsm patients treated with VEN-based regimens. 📍A 4-gene prognostic model (TP53, FLT3-ITD, NRAS, and KRAS) stratified OS outcomes with VEN-AZA treatment in #AMLsm. ashpublications.org/blood/article/…

Full article available right now at Annals of Hematology! Clinical management of patients diagnosed with acute myeloid leukemia treated with venetoclax in combination with hypomethylating agents after achieving a response: a real-life study link.springer.com/article/10.100…

📽️ The AML Hub Steering Committee discuss: Should MRD negativity post remission impact treatment decisions in ELN-intermediate risk AML? Chaired by Jeffrey Lancet. 👉 loom.ly/gfdXO0I Roland B. Walter, MD PhD MS gail roboz Jorge Cortes MD Naval Daver, M.D. Jorge Sierra Jordi Esteve #AMLsm

¡Enhorabuena a nuestro compañero Eduardo Rodríguez Arbolí por este estudio! ¡Atentos al hilo! 👇🏻#Leucemia #SomosHUVR

📢 Nueva edición #LMA #campus🩸📚 Avalado por la @sehh_es PETHEMA y Grupo CETLAM, podrás repasar y actualizar la evidencia en #leucemia #mieloide #aguda desde los aspectos diagnósticos hasta las novedades terapéuticas 🚀 Escanea el QR e inscríbete! Empezamos el 23 Septiembre!

📕Curso de formación en #LMA online acreditado Los doctores Eduardo Rodríguez Arbolí y Concha Prats de nuestro servicio participan en módulos 4 y 6 respectivamente 📆 Inicio el 23 de septiembre Registro en 👇 lmacampus.com Grupo CETLAM @sehh_es PETHEMA HospitalUVRocio